The safe use of intraoperative blood salvage （IBS） in cancer surgery remains controversial. Here, we investigated the kil ing effect of cisplatin combined with hyperthermia on human hepatocarcinoma （HepG2） cel s a...The safe use of intraoperative blood salvage （IBS） in cancer surgery remains controversial. Here, we investigated the kil ing effect of cisplatin combined with hyperthermia on human hepatocarcinoma （HepG2） cel s and erythrocytes from IBS in vitro. HepG2 cel s were mixed with concentrated erythrocytes and pretreated with cisplatin （50, 100, and 200μg/ml） alone at 37 °C for 60 min and cisplatin （25, 50, 100, and 200μg/ml） combined with hyperthermia at 42 °C for 60 min. After pretreatment, the cel viability, colony formation and DNA metabolism in HepG2 and the Na＋-K＋-ATPase activity, 2,3-diphosphoglycerate （2,3-DPG） concentration, free hemoglobin （Hb） level, osmotic fragility, membrane phosphatidylserine externalization, and blood gas variables in erythrocytes were determined. Pretreatment with cisplatin （50, 100, and 200μg/ml） combined with hyperthermia （42 °C） for 60 min significantly decreased HepG2 cel viability, and completely inhibited colony formation and DNA metabolism when the HepG2 cel concentration was 5×104 ml？1 in the erythrocyte （P0.05）. In conclusion, pre-treatment with cisplatin （50μg/ml） combined with hyperthermia （42 °C） for 60 min effectively eliminated HepG2 cel s from IBS but did not significantly affect erythrocytes in vitro.展开更多
基金Project supported by the Scientific Research from Chinese Ministryof Health-Zhejiang Health Department,China(Nos.WKJ2008-2-021and WKJ2013-2-019)
文摘The safe use of intraoperative blood salvage （IBS） in cancer surgery remains controversial. Here, we investigated the kil ing effect of cisplatin combined with hyperthermia on human hepatocarcinoma （HepG2） cel s and erythrocytes from IBS in vitro. HepG2 cel s were mixed with concentrated erythrocytes and pretreated with cisplatin （50, 100, and 200μg/ml） alone at 37 °C for 60 min and cisplatin （25, 50, 100, and 200μg/ml） combined with hyperthermia at 42 °C for 60 min. After pretreatment, the cel viability, colony formation and DNA metabolism in HepG2 and the Na＋-K＋-ATPase activity, 2,3-diphosphoglycerate （2,3-DPG） concentration, free hemoglobin （Hb） level, osmotic fragility, membrane phosphatidylserine externalization, and blood gas variables in erythrocytes were determined. Pretreatment with cisplatin （50, 100, and 200μg/ml） combined with hyperthermia （42 °C） for 60 min significantly decreased HepG2 cel viability, and completely inhibited colony formation and DNA metabolism when the HepG2 cel concentration was 5×104 ml？1 in the erythrocyte （P0.05）. In conclusion, pre-treatment with cisplatin （50μg/ml） combined with hyperthermia （42 °C） for 60 min effectively eliminated HepG2 cel s from IBS but did not significantly affect erythrocytes in vitro.
